• 1. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Study of 2-Bromo-1-(5-methylthiophen-2-yl)ethan-1-one (CAS: 10531-42-7) in Chemical Biology and Pharmaceutical Research

The compound 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one (CAS: 10531-42-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its bromo-substituted ethanone core and 5-methylthiophene moiety, serves as a versatile intermediate in the synthesis of various bioactive compounds. Recent studies have explored its potential applications in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. The unique reactivity of the bromo group and the electron-rich thiophene ring make this compound a valuable building block for medicinal chemistry.

One of the most notable advancements in the study of 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one is its role in the synthesis of novel kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the construction of pyrazole-based inhibitors targeting cyclin-dependent kinases (CDKs). The researchers utilized the bromo group for nucleophilic substitution reactions, enabling the introduction of diverse pharmacophores. The resulting compounds exhibited potent inhibitory activity against CDK2 and CDK9, with IC50 values in the low nanomolar range. This highlights the compound's potential in cancer therapy, where CDK inhibition is a promising strategy.

In addition to its applications in kinase inhibitor development, 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one has also been investigated for its antimicrobial properties. A recent study in Bioorganic & Medicinal Chemistry Letters reported the synthesis of thiazole derivatives using this compound as a key intermediate. The derivatives displayed broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compounds' ability to disrupt bacterial cell wall synthesis, as evidenced by electron microscopy studies. These findings suggest that 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one could serve as a scaffold for developing new antibiotics to address the growing threat of antimicrobial resistance.

From a synthetic chemistry perspective, recent work has focused on optimizing the preparation of 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one to improve yield and purity. A 2022 publication in Organic Process Research & Development described a scalable, one-pot synthesis method using 5-methylthiophene-2-carboxylic acid as the starting material. The new protocol reduced the number of purification steps and increased the overall yield to 85%, making the compound more accessible for large-scale pharmaceutical applications. This methodological advancement is expected to facilitate further research into the compound's biological activities and derivatives.

The safety profile and pharmacokinetic properties of 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one derivatives have also been the subject of recent investigations. A preclinical study published in European Journal of Pharmaceutical Sciences evaluated the metabolic stability and toxicity of several derivatives in vitro. While the parent compound showed moderate hepatic clearance, certain modifications to the thiophene ring significantly improved metabolic stability without compromising biological activity. These structure-activity relationship studies provide valuable insights for future drug design efforts using this chemical scaffold.

Looking ahead, researchers anticipate that 2-bromo-1-(5-methylthiophen-2-yl)ethan-1-one will continue to play an important role in medicinal chemistry. Its structural features offer multiple points for diversification, enabling the exploration of various biological targets. Current research directions include its application in the development of antiviral agents, particularly against RNA viruses, and as a building block for fluorescent probes in chemical biology studies. The compound's versatility and the recent methodological improvements in its synthesis position it as a valuable tool for pharmaceutical innovation in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)